JP2018521628A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521628A5
JP2018521628A5 JP2017556597A JP2017556597A JP2018521628A5 JP 2018521628 A5 JP2018521628 A5 JP 2018521628A5 JP 2017556597 A JP2017556597 A JP 2017556597A JP 2017556597 A JP2017556597 A JP 2017556597A JP 2018521628 A5 JP2018521628 A5 JP 2018521628A5
Authority
JP
Japan
Prior art keywords
seq
domain
tag cassette
amino acid
natural killer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017556597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521628A (ja
JP6985934B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/030281 external-priority patent/WO2016176651A2/en
Publication of JP2018521628A publication Critical patent/JP2018521628A/ja
Publication of JP2018521628A5 publication Critical patent/JP2018521628A5/ja
Priority to JP2021109884A priority Critical patent/JP2021168667A/ja
Application granted granted Critical
Publication of JP6985934B2 publication Critical patent/JP6985934B2/ja
Priority to JP2022199333A priority patent/JP2023036712A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017556597A 2015-04-29 2016-04-29 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用 Expired - Fee Related JP6985934B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021109884A JP2021168667A (ja) 2015-04-29 2021-07-01 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
JP2022199333A JP2023036712A (ja) 2015-04-29 2022-12-14 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154565P 2015-04-29 2015-04-29
US62/154,565 2015-04-29
PCT/US2016/030281 WO2016176651A2 (en) 2015-04-29 2016-04-29 Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021109884A Division JP2021168667A (ja) 2015-04-29 2021-07-01 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用

Publications (3)

Publication Number Publication Date
JP2018521628A JP2018521628A (ja) 2018-08-09
JP2018521628A5 true JP2018521628A5 (enExample) 2019-11-07
JP6985934B2 JP6985934B2 (ja) 2021-12-22

Family

ID=57198772

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017556597A Expired - Fee Related JP6985934B2 (ja) 2015-04-29 2016-04-29 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
JP2021109884A Pending JP2021168667A (ja) 2015-04-29 2021-07-01 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
JP2022199333A Pending JP2023036712A (ja) 2015-04-29 2022-12-14 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021109884A Pending JP2021168667A (ja) 2015-04-29 2021-07-01 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
JP2022199333A Pending JP2023036712A (ja) 2015-04-29 2022-12-14 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用

Country Status (4)

Country Link
US (2) US20180355318A1 (enExample)
EP (2) EP3288569A4 (enExample)
JP (3) JP6985934B2 (enExample)
WO (1) WO2016176651A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
JP7032304B2 (ja) 2015-07-28 2022-03-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
IL258491B2 (en) 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
EP3571221A2 (en) * 2017-01-20 2019-11-27 Juno Therapeutics GmbH Cell surface conjugates and related cell compositions and methods
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CN111051349A (zh) * 2017-09-06 2020-04-21 弗雷德哈钦森癌症研究中心 Strep-tag特异性嵌合受体及其用途
CA3082334A1 (en) * 2017-11-20 2019-05-23 Julius-Maximilians-Universitat Wurzburg Cd19cart cells eliminate myeloma cells that express very low levels of cd19
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Ｃｄ３７特異的キメラ抗原レセプター
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
EP3844191A4 (en) * 2018-08-31 2022-06-15 Seattle Children's Hospital (DBA Seattle Children's Research Institute) METHODS AND COMPOSITIONS USING CHIMERIC B7H3 ANTIGEN RECEPTORS
CA3128871A1 (en) * 2019-02-09 2020-08-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically modified hematopoietic stem and progenitor cells (hspcs) and mesenchymal cells as a platform to reduce or prevent metastasis, treat autoimmune and inflammatory disorders, and rebalance the immune milieu_and dysregulated niches
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
EP4161536A4 (en) 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CN114733455B (zh) * 2022-04-15 2023-02-14 北京田园奥瑞生物科技有限公司 一种利用生物改性β-环糊精纳米磁颗粒进行快速哺乳动物精子分型的方法
PE20260290A1 (es) 2023-03-31 2026-02-10 Abelzeta Inc Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma
CN118853562B (zh) * 2024-07-11 2025-08-29 中国科学院广州生物医药与健康研究院 一种靶向cd19的car-nk细胞及其制备方法和应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5856441A (en) 1991-05-03 1999-01-05 Yale University Serrate fragments and derivatives
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5869282A (en) 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
WO1993012141A1 (en) 1991-12-11 1993-06-24 Yale University Nucleotide and protein sequences of the serrate gene and methods based thereon
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
EP0737207B1 (en) 1994-01-11 2004-09-22 Dyax Corporation Inhibitors of human plasmin derived from the kunitz domains
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5877299A (en) 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
DK0861261T3 (da) 1995-06-28 2009-12-14 Imp Cancer Res Tech Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
CA2347973C (en) * 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
WO2002059285A1 (en) 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
ES2559763T3 (es) * 2002-09-10 2016-02-15 Affimed Gmbh Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US8252587B2 (en) 2004-10-25 2012-08-28 Celerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
US20090220501A1 (en) * 2006-01-30 2009-09-03 Fey Georg H Anti-CD19 Antibody, Immunotoxin and Treatment Method
WO2007095594A2 (en) 2006-02-14 2007-08-23 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
KR20090021217A (ko) 2006-06-14 2009-02-27 추가이 세이야쿠 가부시키가이샤 조혈 줄기세포 증가 촉진제
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
ES2621181T3 (es) * 2008-11-21 2017-07-03 Lallemand Hungary Liquidity Management Llc Levaduras que expresan celulasas para la sacarificación y fermentación simultáneas utilizando celulosa
CA2753158A1 (en) * 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP3097916B1 (en) 2010-04-09 2021-07-07 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function
EP3590520B1 (en) 2010-04-09 2021-12-29 Fred Hutchinson Cancer Research Center Compositions for providing hematopoietic function without hla matching
WO2012136231A1 (en) * 2010-09-08 2012-10-11 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US20160145348A1 (en) * 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US20160250258A1 (en) * 2013-10-31 2016-09-01 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
NZ759969A (en) * 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof

Similar Documents

Publication Publication Date Title
JP2021519580A5 (enExample)
JP2021519301A5 (enExample)
JP2025028239A5 (enExample)
JP2017500009A5 (enExample)
HRP20201906T1 (hr) Označene kimerne efektorske molekule i njihovi receptori
RU2020135106A (ru) Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения
FI3334765T3 (fi) Yksidomeenivasta-aineisiin perustuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
RU2019126655A (ru) Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль
RU2020135107A (ru) Клеточные иммунотерапевтические композиции и их применения
RU2016121174A (ru) МОДИФИЦИРОВАННЫЕ ГЕМОПОЭТИЧЕСКИЕ СТВОЛОВЫЕ КЛЕТКИ/КЛЕТКИ-ПРЕДШЕСТВЕННИКИ И Не-Т ЭФФЕКТОРНЫЕ КЛЕТКИ, И ИХ ПРИМЕНЕНИЕ
JP2022542543A5 (enExample)
JP2019532017A5 (enExample)
JP2015527070A5 (enExample)
JP2017501702A5 (enExample)
JP2018525033A5 (enExample)
JP2021514631A5 (enExample)
CA3016287A1 (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
JP2020517295A5 (enExample)
JP2022542559A5 (enExample)
JP2022507295A5 (enExample)
JP2024023228A5 (enExample)
JP2019503200A (ja) 癌の治療のための組成物及び方法
CN115232209B (zh) 靶向gprc5d的抗体及其用途
JP2017524367A5 (enExample)
JP2021526844A5 (enExample)